We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
- Authors
Carey, Lisa A; Rugo, Hope S; Marcom, P Kelly; Mayer, Erica L; Esteva, Francisco J; Ma, Cynthia X; Liu, Minetta C; Storniolo, Anna Maria; Rimawi, Mothaffar F; Forero-Torres, Andres; Wolff, Antonio C; Hobday, Timothy J; Ivanova, Anastasia; Chiu, Wing-Keung; Ferraro, Madlyn; Burrows, Emily; Bernard, Philip S; Hoadley, Katherine A; Perou, Charles M; Winer, Eric P
- Abstract
Epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only subtype without established targeted therapy.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Vol 30, Issue 21, p2615
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.34.5579